about
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic diseaseMithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factorsEndothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.Multiple myeloma--an update on diagnosis and treatment.SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.Biological aspects of angiogenesis in multiple myeloma.Bone mass of the calvarium.Cellular immunotherapy in multiple myeloma: lessons from preclinical models.Galectin expression in cancer diagnosis and prognosis: A systematic review.Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.Acute interstitial nephritis associated with salmonellosis.The effects of forodesine in murine and human multiple myeloma cells.Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical studyAutotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma.Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity.Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in OsteoclastsFactor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcerAc-SDKP: linking cardiac remodeling to hematological malignanciesNeighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cellsCatheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion portsDiffuse xanthomatosis as a presenting feature of multiple myeloma[Retroperitoneal fibrosis and multiple myeloma: fortuitous association?]Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphomaA novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA)Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis
P50
Q27329429-9AA5481B-97B7-4251-B307-EA78D9907D2FQ28487743-E7AE4C30-6331-4EA5-9D75-2444A88E2733Q33253492-4E7D46B5-6D99-46F6-90C0-FDEE715F9CADQ33587558-A90ECB9A-9909-452A-B9D6-B3E572C59B7DQ33885555-D0A7F2AC-E95E-4EB3-9B8F-47A9A7FC1E0EQ33956990-DED143DB-D2F8-44DF-8BA5-1EA6915AE191Q34450381-E3946927-BD71-43AD-8A08-D7617AD28AE3Q34557219-6B2A1AB9-B25C-482F-A13B-94118B96AE32Q37064425-BB6BB077-D859-4FFA-ADA1-FC8C5D278D7EQ37219747-237AC2A6-15E2-4AC0-9249-C8417DAA52B6Q37327588-C562CDF8-AEE9-4BA8-844C-9A61CCCC2091Q37437357-04D507B5-1BBE-4AF6-8B56-7AD32F94D72BQ37676265-050AE0EA-74BB-46E8-82B4-284C735F2C01Q37956524-59EB3E91-1711-472C-B807-C7D6D2079029Q38063795-221818C8-96F3-47D8-A5FD-3F03D3224FC9Q38238588-75ACF182-DF4A-4861-9AF9-3347DAA7BA7AQ38394821-EABB9238-5761-4DC8-97B5-C2A637146B42Q38681463-066F73AA-0D72-4866-AE6D-4417CF38B380Q38749233-D24D7AC8-C21D-4C69-8D96-82D34B547902Q38875327-E9FF0780-DF9E-4CE6-B8E4-C3CD755AA651Q39175226-D2165EF0-9995-4AE6-839F-D3D773B2E895Q40149390-D3FFBF66-06A3-4279-B45A-E5260C464CFAQ40481250-51D4A645-C1D0-418C-A40C-1E493D637C8EQ41923743-52C59474-1ADE-47C5-AB75-D4B97AC8FBD7Q42180809-0F44ACD4-B339-4C2D-B865-9D6718501618Q42362041-51A3F3AD-7138-4E01-9FDC-DCBEE24F4B16Q43376041-BF4D2191-6476-489A-B518-1982F2FF36A0Q45059358-8B58E636-6CEE-48EF-8929-E99D2D86D51BQ48036342-1ECF4D39-C267-4175-9608-4D8E26AAE362Q48232766-F7F06A80-59DC-4BB1-8415-B187AFA690D7Q64108089-F0294B79-FAD3-4160-8907-831E62013083Q73470703-5B5B81AD-1034-4A44-B2D7-925BDFE348A3Q79300622-46D5E167-21E0-42F2-8809-11953FD542F4Q80008493-E47890F0-E7D2-4C39-B2F6-1085FDEC04D2Q80989998-9ABE4FFC-CF22-4330-89DB-18A8D195EFBAQ82264285-257C4B34-B03F-47C3-A01A-3A7B33CFF034Q83974272-E38CE793-01CD-48D4-8D9D-99935AAFD92DQ84086435-F58B9833-F30D-46D2-82CB-6F9884CBF3D2Q85631274-42874DE1-B041-457F-A316-3D74B3360823Q87151845-B79B7FEE-C206-43EA-A4C9-81C202A75E16
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jo Caers
@ast
Jo Caers
@en
Jo Caers
@es
Jo Caers
@sl
type
label
Jo Caers
@ast
Jo Caers
@en
Jo Caers
@es
Jo Caers
@sl
prefLabel
Jo Caers
@ast
Jo Caers
@en
Jo Caers
@es
Jo Caers
@sl
P106
P1153
12774892000
P31
P496
0000-0002-3175-1195